Quantum BioPharma (QNTM)
Market Price (1/30/2026): $4.97 | Market Cap: $18.9 MilSector: Health Care | Industry: Biotechnology
Quantum BioPharma (QNTM)
Market Price (1/30/2026): $4.97Market Cap: $18.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Gene Editing & Therapy, Show more. | Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -166% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -19 Mil | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -158% | ||
| High stock price volatilityVol 12M is 198% | ||
| Key risksQNTM key risks include [1] significant financial instability due to consistent losses and a lack of revenue, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -166% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -19 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -158% |
| High stock price volatilityVol 12M is 198% |
| Key risksQNTM key risks include [1] significant financial instability due to consistent losses and a lack of revenue, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Quantum BioPharma (QNTM) stock has lost about 70% since 9/30/2025 because of the following key factors:
1. Significant Miss in Q3 2025 Earnings: Quantum BioPharma reported its Q3 2025 earnings on November 7, 2025, disclosing an Earnings Per Share (EPS) of -$1.25. This figure substantially missed the consensus estimate of -$0.20 by $1.05, indicating underlying financial performance issues that likely eroded investor confidence.
2. Uncertainty and Lack of Liquidity for Litigation-Linked Contingent Value Rights (CVRs): On October 20, 2025, the company reiterated the record date for the distribution of Contingent Value Rights (CVRs) related to a $700 million legal action alleging stock price manipulation. While the lawsuit seeks significant damages, the CVRs are not listed on any exchange, and there is no guarantee that any net proceeds will be received or that payments will be made. This uncertainty, coupled with the CVRs' illiquid nature, likely led investors to discount their value heavily or view them as an unreliable future asset, contributing to selling pressure. The company's history of stock declines even after positive clinical news, as highlighted by reports in November 2025 concerning the $700M legal battle, further suggests a deep-seated lack of investor trust.
Show more
1. Significant Miss in Q3 2025 Earnings: Quantum BioPharma reported its Q3 2025 earnings on November 7, 2025, disclosing an Earnings Per Share (EPS) of -$1.25. This figure substantially missed the consensus estimate of -$0.20 by $1.05, indicating underlying financial performance issues that likely eroded investor confidence.
2. Uncertainty and Lack of Liquidity for Litigation-Linked Contingent Value Rights (CVRs): On October 20, 2025, the company reiterated the record date for the distribution of Contingent Value Rights (CVRs) related to a $700 million legal action alleging stock price manipulation. While the lawsuit seeks significant damages, the CVRs are not listed on any exchange, and there is no guarantee that any net proceeds will be received or that payments will be made. This uncertainty, coupled with the CVRs' illiquid nature, likely led investors to discount their value heavily or view them as an unreliable future asset, contributing to selling pressure. The company's history of stock declines even after positive clinical news, as highlighted by reports in November 2025 concerning the $700M legal battle, further suggests a deep-seated lack of investor trust.
Show more
Stock Movement Drivers
Fundamental Drivers
The -70.3% change in QNTM stock from 9/30/2025 to 1/29/2026 was primarily driven by a -20.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 1292026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.40 | 4.87 | -70.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 3 | 4 | -20.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 1/29/2026| Return | Correlation | |
|---|---|---|
| QNTM | -70.3% | |
| Market (SPY) | 4.2% | 18.7% |
| Sector (XLV) | 10.5% | 2.0% |
Fundamental Drivers
The -76.0% change in QNTM stock from 6/30/2025 to 1/29/2026 was primarily driven by a -34.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 1292026 | Change |
|---|---|---|---|
| Stock Price ($) | 20.25 | 4.87 | -76.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 4 | -34.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 1/29/2026| Return | Correlation | |
|---|---|---|
| QNTM | -76.0% | |
| Market (SPY) | 12.6% | 22.3% |
| Sector (XLV) | 14.6% | 1.8% |
Fundamental Drivers
The 32.3% change in QNTM stock from 12/31/2024 to 1/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312024 | 1292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.68 | 4.87 | 32.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 4 | -75.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2024 to 1/29/2026| Return | Correlation | |
|---|---|---|
| QNTM | 32.3% | |
| Market (SPY) | 19.5% | 18.6% |
| Sector (XLV) | 13.3% | 4.7% |
Fundamental Drivers
The -90.5% change in QNTM stock from 12/31/2022 to 1/29/2026 was primarily driven by a -84.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312022 | 1292026 | Change |
|---|---|---|---|
| Stock Price ($) | 51.25 | 4.87 | -90.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 4 | -84.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2022 to 1/29/2026| Return | Correlation | |
|---|---|---|
| QNTM | -90.5% | |
| Market (SPY) | 88.2% | 14.6% |
| Sector (XLV) | 18.5% | 6.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| QNTM Return | -35% | -23% | 17% | -94% | 98% | -33% | -95% |
| Peers Return | -16% | -28% | -41% | -66% | -32% | 8% | -91% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| QNTM Win Rate | 33% | 42% | 50% | 17% | 42% | 0% | |
| Peers Win Rate | 36% | 50% | 53% | 29% | 56% | 100% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| QNTM Max Drawdown | -38% | -29% | -2% | -95% | -21% | -33% | |
| Peers Max Drawdown | -30% | -45% | -60% | -67% | -49% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ACSB, AKTS, ALPS, APRI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/29/2026 (YTD)
How Low Can It Go
| Event | QNTM | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -81.2% | -25.4% |
| % Gain to Breakeven | 431.2% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -87.5% | -33.9% |
| % Gain to Breakeven | 698.4% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -94.1% | -19.8% |
| % Gain to Breakeven | 1595.1% | 24.7% |
| Time to Breakeven | 1 days | 120 days |
Compare to VRTX, ACSB, AKTS, ALPS, APRI
In The Past
Quantum BioPharma's stock fell -81.2% during the 2022 Inflation Shock from a high on 2/10/2021. A -81.2% loss requires a 431.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Quantum BioPharma (QNTM)
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
AI Analysis | Feedback
Here are 1-3 brief analogies for Quantum BioPharma (QNTM):
- QNTM is like an early-stage Amgen or Gilead Sciences, focused on developing new therapies but much smaller and earlier in its pipeline.
- QNTM is like the dedicated 'research & development arm' of a major pharmaceutical company like Pfizer or Merck, but operating as an independent, early-stage entity.
- QNTM is like a 'drug startup' aiming to develop breakthrough medicines, similar to how Moderna was focused on innovative drug platforms before its major successes.
AI Analysis | Feedback
The company "Quantum BioPharma" with the stock symbol QNTM could not be identified as a publicly traded entity on major stock exchanges or financial databases.
Therefore, I am unable to identify its major products or services as requested.
AI Analysis | Feedback
The company symbol QNTM belongs to Quantum Corporation, not Quantum BioPharma. Assuming the inquiry is for Quantum Corporation (NASDAQ: QNTM), here is the information regarding its major customers.
Quantum Corporation primarily sells its data storage, management, and protection solutions to other companies and organizations (B2B) rather than individuals. The company does not publicly disclose specific names of its major customers, as no single customer accounts for 10% or more of its total net revenue, according to its latest financial filings.
However, Quantum Corporation serves a diverse range of customers across various industries that require robust solutions for managing large volumes of unstructured data. These customer categories include:
- Media and Entertainment Companies: Including studios, post-production houses, and broadcasters that need to store and manage vast amounts of video content, raw footage, and archives.
- Government Agencies and Scientific Research Institutions: Organizations involved in surveillance, defense, academic research, genomics, and high-performance computing that generate and analyze massive datasets.
- Enterprises and Cloud Providers: Businesses across various sectors, including financial services and education, as well as cloud service providers, that require scalable storage, data protection, and archiving solutions for their general IT environments.
AI Analysis | Feedback
null
AI Analysis | Feedback
Zeeshan Saeed, Chief Executive Officer, Founder & Executive Co-Chairman
Zeeshan Saeed is a co-founder of Quantum BioPharma (formerly FSD Pharma Inc.), established in 1994, and was instrumental in securing initial seed capital and transitioning the company into a publicly traded entity. He also serves as Independent Co-Chairman of Unbuzzd Wellness Inc. as of August 2023.
Donal Carroll, Chief Financial Officer
Donal Carroll was appointed Chief Financial Officer of Quantum BioPharma effective August 30, 2024. He previously held the role of interim CFO in 2018, then permanent CFO from December 2019 to May 2021, and COO from August 2021. Mr. Carroll brings over 20 years of corporate finance leadership and public company experience, including experience in syndicate investing in both equity and debt securities.
Anthony Durkacz, Co-Founder & Executive Co-Chairman
Anthony Durkacz is a co-founder of Quantum BioPharma and has served as a director and Executive Vice-President of First Republic Capital Corporation since 2014. Prior to co-founding the company, he was President of Capital Ideas Investor Relations. Mr. Durkacz also previously served as the Chief Financial Officer and a director of Snipp Interactive Inc., where he was instrumental in its financing and public listing.
Dr. Lakshmi P. Kotra, CEO of Lucid & Director
Dr. Lakshmi P. Kotra joined Quantum BioPharma as CEO of its wholly-owned subsidiary, Lucid, following the acquisition of Lucid Psycheceuticals in September 2021. He is a Senior Scientist at Krembil Brain Institute, University Health Network, and a Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra holds a Ph.D. in Pharmacy/Medicinal Chemistry from the University of Georgia.
Nathan Coyle, Controller
Nathan Coyle joined Quantum BioPharma Inc. in 2020 as Corporate Controller and later held the role of Interim Chief Financial Officer in 2021. He possesses 15 years of executive business experience as a finance leader in both public and private sector roles. Previously, Mr. Coyle was with Illinois Tool Works (NYSE:ITW), where he played a key role in organizational restructuring, growth shaping, and business streamlining within the industrial packaging segment.
AI Analysis | Feedback
The key risks to Quantum BioPharma's business are as follows:
- Financial Instability and Lack of Revenue: Quantum BioPharma faces significant financial challenges, marked by a lack of revenue growth, consistent losses over the past three years, and negative earnings per share. The company's net loss for the year ended December 31, 2024, was $14.9 million USD, despite some improvements in operating efficiency. The business is primarily financed through equity and continues to incur substantial losses. Sustaining operations and future growth hinges on the company's ability to generate significant revenue streams, particularly from the approval and commercialization of its products.
- Market Manipulation Lawsuit and Stock Volatility: The company is engaged in a substantial $700 million lawsuit against major Canadian banks, alleging stock market manipulation through "spoofing" tactics that artificially suppressed its stock price. This ongoing legal battle introduces considerable uncertainty into Quantum BioPharma's outlook and has been associated with high stock volatility and a significant decline in share price over the past year. The outcome of this lawsuit, while potentially transformative, is not guaranteed.
- Regulatory Challenges and Inherent Uncertainties of Drug Development: As a biopharmaceutical company, Quantum BioPharma is exposed to the inherent risks of the biotechnology sector, including stringent regulatory hurdles and the unpredictable nature of drug development. The successful advancement of its clinical assets, such as the "unbuzzd" product, and the ability to secure regulatory approvals are critical for its future viability and revenue generation. Risks also include the possibility of the company not retaining full development rights for its products or its clinical programs failing to progress as anticipated.
AI Analysis | Feedback
nullAI Analysis | Feedback
null
AI Analysis | Feedback
Quantum BioPharma (QNTM) is expected to drive future revenue growth over the next 2-3 years through several key initiatives, primarily focusing on its product pipeline and strategic market expansion.
- Advancement and Commercialization of Lucid-MS: A significant driver of future revenue is the progression and eventual commercialization of Lucid-MS, Quantum BioPharma's lead drug candidate for multiple sclerosis. This orally administered compound has shown promise in preclinical models for preventing and reversing myelin degradation, a hallmark of MS. The company is preparing for a Phase 2 trial, and the global MS drug market is projected to grow substantially, potentially exceeding $41 billion by 2033. Quantum BioPharma retains full rights to develop this product for pharmaceutical uses, offering significant revenue potential.
- Growth and Expansion of the Unbuzzdâ„¢ Product Line: The consumer wellness product, Unbuzzdâ„¢, which helps accelerate alcohol metabolism and reduce hangover symptoms, is a near-term revenue engine. Launched in late 2024, Unbuzzdâ„¢ is already generating organically growing revenue through online sales. Future growth is anticipated from its planned retail expansion, supported by a Reg D financing round by its licensee, Unbuzzd Wellness Inc., and potential market entry into Canada, where Health Canada approval is pending. Building on this platform, the development and commercialization of the REKVRY program, a clinical-grade therapeutic for acute alcohol intoxication, also represents a significant new product opportunity.
- Launch and Market Penetration of Qlarity: The approval of Qlarity, a natural health product, by Health Canada enables its sale in the Canadian market. This new product launch in a new geographical market is expected to contribute to revenue growth as the company expands its reach and establishes market penetration for Qlarity.
- Strategic Asset Management: While not directly related to biopharmaceutical product sales, Quantum BioPharma's strategic management of its digital assets, particularly its cryptocurrency portfolio, has generated gains and contributes to the company's financial strength and overall revenue. The company has significantly increased its digital assets and has realized profits from these investments, which management aims to continue leveraging to sustain operations and support its pipeline development.
AI Analysis | Feedback
Share Issuance
- On November 1, 2025, Quantum BioPharma Ltd. initiated an at-the-market (ATM) offering, seeking to raise up to US$21,225,000 through the issuance of Class B Subordinate Voting Shares.
Outbound Investments
- Quantum BioPharma spun out its unbuzzd™ product to Celly Nutrition Corp. (now Unbuzzd Wellness Inc.) and retains a 20.10% ownership stake in Unbuzzd Wellness Inc. as of June 30, 2025.
- The agreement with Unbuzzd Wellness Inc. includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma reach $250 million, after which the royalty rate will decrease to 3% in perpetuity.
- The company maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial property.
Capital Expenditures
- The reported value of physical assets on Quantum BioPharma's balance sheet is approximately US$228.2 thousand.
- Research and Development expenses were $6.083 million for the most recent reporting period, following $3.859 million, $6.911 million, and $6.328 million in prior periods.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.26 |
| Mkt Cap | 60.8 |
| Rev LTM | 5,862 |
| Op Inc LTM | -56 |
| FCF LTM | 1,664 |
| FCF 3Y Avg | 1,026 |
| CFO LTM | 1,855 |
| CFO 3Y Avg | 1,204 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.3% |
| Rev Chg 3Y Avg | 10.5% |
| Rev Chg Q | 11.0% |
| QoQ Delta Rev Chg LTM | 2.7% |
| Op Mgn LTM | -0.8% |
| Op Mgn 3Y Avg | 26.2% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 31.7% |
| CFO/Rev 3Y Avg | 23.1% |
| FCF/Rev LTM | 28.5% |
| FCF/Rev 3Y Avg | 19.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 60.8 |
| P/S | 10.4 |
| P/EBIT | 13.3 |
| P/E | 16.2 |
| P/CFO | 15.3 |
| Total Yield | -75.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -45.9% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 3.1% |
| 3M Rtn | -2.1% |
| 6M Rtn | -2.1% |
| 12M Rtn | 36.7% |
| 3Y Rtn | 23.3% |
| 1M Excs Rtn | 2.1% |
| 3M Excs Rtn | -3.2% |
| 6M Excs Rtn | -11.6% |
| 12M Excs Rtn | 22.2% |
| 3Y Excs Rtn | -48.7% |
Price Behavior
Price Behavior
| Market Price | $4.87 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/08/2018 | |
| Distance from 52W High | -86.1% | |
| 50 Days | 200 Days | |
| DMA Price | $7.87 | $13.88 |
| DMA Trend | up | down |
| Distance from DMA | -38.1% | -64.9% |
| 3M | 1YR | |
| Volatility | 155.4% | 199.2% |
| Downside Capture | 532.17 | 250.29 |
| Upside Capture | -67.95 | 265.93 |
| Correlation (SPY) | 19.3% | 18.6% |
QNTM Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.79 | 5.08 | 3.31 | 3.56 | 2.02 | 1.53 |
| Up Beta | 8.92 | 5.75 | 3.75 | 2.59 | 1.29 | 0.95 |
| Down Beta | 0.32 | 2.01 | 2.27 | 2.63 | 1.31 | 1.20 |
| Up Capture | 302% | 428% | 88% | 246% | 1090% | 184% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 10 | 16 | 24 | 51 | 113 | 322 |
| Down Capture | 739% | 508% | 385% | 339% | 158% | 112% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 12 | 25 | 40 | 75 | 137 | 408 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QNTM | |
|---|---|---|---|---|
| QNTM | 92.8% | 198.7% | 1.11 | - |
| Sector ETF (XLV) | 6.4% | 17.2% | 0.20 | 5.4% |
| Equity (SPY) | 15.9% | 19.2% | 0.64 | 18.3% |
| Gold (GLD) | 96.0% | 20.8% | 3.15 | 5.4% |
| Commodities (DBC) | 15.3% | 15.5% | 0.72 | 9.4% |
| Real Estate (VNQ) | 3.8% | 16.5% | 0.05 | 13.2% |
| Bitcoin (BTCUSD) | -12.7% | 39.6% | -0.25 | 10.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QNTM | |
|---|---|---|---|---|
| QNTM | -48.0% | 128.3% | -0.00 | - |
| Sector ETF (XLV) | 7.1% | 14.5% | 0.31 | 7.8% |
| Equity (SPY) | 14.1% | 17.1% | 0.66 | 15.0% |
| Gold (GLD) | 23.5% | 15.8% | 1.20 | 3.9% |
| Commodities (DBC) | 13.3% | 18.7% | 0.58 | 7.4% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 11.4% |
| Bitcoin (BTCUSD) | 21.8% | 57.5% | 0.57 | 9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QNTM | |
|---|---|---|---|---|
| QNTM | 1.5% | 5,072.9% | 0.37 | - |
| Sector ETF (XLV) | 10.5% | 16.6% | 0.52 | -0.1% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 0.0% |
| Gold (GLD) | 16.8% | 14.9% | 0.94 | 1.2% |
| Commodities (DBC) | 9.2% | 17.6% | 0.43 | 0.4% |
| Real Estate (VNQ) | 6.1% | 20.8% | 0.26 | 0.3% |
| Bitcoin (BTCUSD) | 71.2% | 66.5% | 1.10 | -1.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 6-K |
| 06/30/2025 | 08/07/2025 | 6-K |
| 03/31/2025 | 05/14/2025 | 6-K |
| 12/31/2024 | 03/28/2025 | 20-F |
| 09/30/2024 | 11/12/2024 | 6-K |
| 06/30/2024 | 08/14/2024 | 6-K |
| 03/31/2024 | 05/15/2024 | 6-K |
| 12/31/2023 | 04/02/2024 | 20-F |
| 09/30/2023 | 11/15/2023 | 6-K |
| 06/30/2023 | 07/20/2023 | 6-K |
| 03/31/2023 | 05/15/2023 | 6-K |
| 12/31/2022 | 03/31/2023 | 20-F |
| 09/30/2022 | 11/14/2022 | 6-K |
| 06/30/2022 | 08/12/2022 | 6-K |
| 03/31/2022 | 05/13/2022 | 6-K |
| 12/31/2021 | 03/31/2022 | 20-F |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.